BioSpace News Archive

GeneQuantum Healthcare has recently received the US IND approval for its in-house developed next generation antibody drug conjugate asset, GQ1001.

Synthace Ltd, the company behind Antha, the cloud-based software platform for automating and improving the success rate of biological processes, and the Tecan Group announce a partnership to deepen the integration between Synthace’s Antha software and Tecan’s Te-Chrom™ automated chromatography system to unlock the full potential of miniaturized protein purification.

Harbour BioMed announced the appointment of Dr. Jon Wigginton M.D., to the company’s scientific advisory board.

MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces that the Centers for Medicare & Medicaid Services (CMS) has assigned an Ambulatory Payment Classification (APC) code 5722 for the MolecuLight i:X imaging procedure for point-of-care real-time fluorescence wound imaging for bacterial presence, location and load

BIOLASE, Inc. announced the closing on June 10, 2020 of its previously announced registered direct offering of approximately $6.9 million of its common stock in a registered direct offering priced at-the-market under Nasdaq rules and warrants to purchase common stock in a concurrent private placement.

Praxis Precision Medicines, a clinical-stage, genetic neuroscience company, announced the promotion of Stuart Chaffee, Ph.D., to chief financial officer, effective immediately.

Aerie Pharmaceuticals, Inc. announced that Peter J. McDonnell, M.D., has been appointed to the Company’s Board of Directors and will also be a member of both the Nominating and Corporate Governance and Compensation Committees of the Board.

LivaNova PLC announced its entry into a five-year $450 million senior secured credit facility through its wholly owned U.S. subsidiary, LivaNova USA, Inc. with funds managed by affiliates of Ares Management Corporation, as administrative agent and collateral agent.

Antares Pharma, Inc., announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on Thursday, June 18, 2020 at 9:40 a.m. Eastern Time.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Linda Bain has joined its Board of Directors.